Skyclarys: HSE to reconsider Friedreich’s Ataxia drug funding

When will a decision on Skyclarys be made? The HSE Drugs Group meets on Tuesday to reconsider whether to fund Skyclarys, the first treatment shown to slow the progression of Friedreich’s Ataxia. Around 200 people in Ireland live with the rare neurological disease and have campaigned for the drug to be made available on the […]